Nama's AI scorecard currently rates Absci Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ABSI report earnings?

Absci's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.20.

What is the ABSI price target?

The median analyst price target from 11 analysts is $15.00, with a range of $10.00 – $20.00.

Is ABSI Shariah compliant?

Nama's AAOIFI-style screen reads Absci as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Absci (ABSI)

Healthcare · Biotechnology · NASDAQ

Absci (ABSI) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.75B and a free-cash-flow yield of -6.8%. Over the most recent reported fiscal year, revenue declined 38.2%. Nama's AI scorecard rates it Sell, 2.2 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 2.2/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +156.8% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-43.9%

How far the last close sits under the highest price of the past five years.

Market cap	$1.75B
Trailing P/E	—
Price / book	7.1
Price / sales	1017.0
FCF yield	-6.8%
Dividend yield	—
Gross margin	0.0%
Operating margin	-10741.5%
Net margin	0.0%
Revenue growth (YoY)	-38.2%
Revenue growth (3-yr annual)	-21.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ABSI earnings

Next report: Nov 12, 2026 (Q3 2026, EPS estimate -$0.20). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 11, 2026	-$0.21	-$0.20	-5.0%	$318,000
Q1 2026	May 7, 2026	-$0.19	-$0.20	+5.0%	$215,000
Q4 2025	Mar 24, 2026	-$0.23	-$0.17	-35.3%	$650,000
Q3 2025	Nov 12, 2025	-$0.20	-$0.21	+4.8%	$378,000

ABSI analyst price target

Median target $15.00 from 11 analysts, ranging $10.00 – $20.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ABSI data on Nama Insights →

ABSI FAQ

Is ABSI a buy?: Nama's AI scorecard currently rates Absci Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ABSI report earnings?: Absci's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.20.
What is the ABSI price target?: The median analyst price target from 11 analysts is $15.00, with a range of $10.00 – $20.00.
Is ABSI Shariah compliant?: Nama's AAOIFI-style screen reads Absci as Can't Tell. A figure the screen needs is missing, so it can't tell.